Sweden's Camurus Q2 revenue beats estimates on Buvidal and Brixadi demand

Camurus AB

15/07/2026 06:10

Overview
Sweden biopharma firm's Q2 revenue rose 4% yr/yr, beating analyst expectations
Product sales grew 13% yr/yr, driven by Buvidal and Brixadi royalty growth
Company received FDA Complete Response Letter for CAM2029 NDA for acromegaly in US

Outlook
Camurus reiterates its financial outlook for 2026
Company sees positive commercial outlook for H2 2026, citing portfolio progress and milestones
Camurus expects stronger demand across key European markets in the second half

Result Drivers
BUVIDAL GROWTH - Co said renewed Buvidal growth supported Q2 results
BRIXADI ROYALTY INCREASE - Continued Brixadi royalty growth in the US contributed to higher revenue
EUROPEAN DEMAND - Stronger demand across key European markets drove product sales growth

Company press release: ID:nWkr9hTkhK

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
SEK 702 mln
SEK 632.80 mln (5 Analysts)
Q2 EBIT
 
SEK 293 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Camurus AB is SEK750.00, about 42.5% above its July 14 closing price of SEK526.50
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 25 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)